Analyst Price Targets — SMTI
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| August 18, 2025 10:46 am | Yi Chen | H.C. Wainwright | $54.00 | $29.68 | StreetInsider | Sanara MedTech (SMTI) PT Raised to $54 at H.C. Wainwright |
| March 26, 2024 5:45 pm | Ross Osborn | Cantor Fitzgerald | $44.00 | $36.75 | StreetInsider | Sanara MedTech (SMTI) PT Lowered to $44 at Cantor Fitzgerald |
Latest News for SMTI
Sanara MedTech Inc. (SMTI) Q4 2025 Earnings Call Transcript
Sanara MedTech Inc. (SMTI) came out with quarterly earnings of $0.04 per share, missing the Zacks Consensus Estimate of $0.11 per share. This compares to a loss of $0.18 per share a year ago.
FORT WORTH, TX, March 24, 2026 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. (“Sanara,” the “Company,” “we,” “our” or “us”) (Nasdaq: SMTI), a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical market, today reported its financial results for the fourth quarter and full year ended December 31, 2025,…
Study demonstrates cost savings and improved health outcomes associated with the use of CellerateRX ® as an adjunct to the standard of care for high-risk spinal surgery patients, compared to the standard of care alone
FORT WORTH, TX, March 03, 2026 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. (“Sanara,” the “Company,” “we,” “our” or “us”) (Nasdaq: SMTI), a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical market, announced today that it will report its fourth quarter and full year 2025 financial results on…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for SMTI.
U.S. House Trading
No House trades found for SMTI.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.